Drugs / TJ101
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT07300436 | Jan → Mar 2026 | — | TJ Biopharma Co., Ltd. | Completed | No outcome recorded |
| Phase 1 | NCT07181473 | Aug 2025 → Dec 2026 expected | esophageal cancer, non-small cell lung carcinoma, prostate cancer | Phrontline Biopharma | Recruiting | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT04633057 | Jan 2021 → Jul 2023 | pituitary deficiency | TJ Biopharma Co., Ltd. | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | TJ101 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07300436 ↗ |
| Known as | Recombinant Human Somatropin Injection | “TJ101/ Recombinant Human Somatropin Injection treatment: after screening, subjects will be randomized to receive TJ101 1.2 mg/kg once a week until 52 weeks back site,...” NCT04633057 ↗ |
| Modality | Protein / enzyme biologic | “Recombinant Human Somatropin Injection” NCT04633057 ↗ |
| Route | Intravenous | “Receive intravenous (IV) infusions of TJ101” NCT07181473 ↗ |
| Target | EGFR | “targeting EGFR” NCT07181473 ↗ |